GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Proteomics International Laboratories Ltd (ASX:PIQ) » Definitions » Current Deferred Revenue

Proteomics International Laboratories (ASX:PIQ) Current Deferred Revenue : A$0.25 Mil (As of Jun. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Proteomics International Laboratories Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Proteomics International Laboratories's current deferred revenue for the quarter that ended in Jun. 2024 was A$0.25 Mil.

Proteomics International Laboratories Current Deferred Revenue Historical Data

The historical data trend for Proteomics International Laboratories's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Proteomics International Laboratories Current Deferred Revenue Chart

Proteomics International Laboratories Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.27 0.36 0.37 0.25

Proteomics International Laboratories Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.36 - 0.37 - 0.25

Proteomics International Laboratories Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of Proteomics International Laboratories's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Proteomics International Laboratories Business Description

Traded in Other Exchanges
N/A
Address
6 Verdun Street, QEII Medical Centre, QQ Block, Nedlands, Perth, WA, AUS, 6009
Proteomics International Laboratories Ltd is a biological research and drug discovery company. The company specializes in the area of proteomics which is the industrial-scale study of the structure and function of proteins. Its operations are divided into PromarkerD which targets the diabetes epidemic and is a predictive diagnostic test for diabetic kidney disease, a progressive disorder found in one in three adults with diabetes; its proprietary biomarker discovery platform called Promarker, which searches for protein fingerprints in a sample; and Analytical Services that are specialist contract research focusing on biosimilars quality control and pharmacokinetic testing for clinical trials.

Proteomics International Laboratories Headlines

No Headlines